Start Date
March 31, 2016
Primary Completion Date
March 31, 2017
Study Completion Date
March 31, 2017
Vigil™
Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10\^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
Nivolumab
Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
Mary Crowley Cancer Research Centers, Dallas
Texas Oncology, P.A., Texas Cancer Center, Abilene
Cancer Care Northwest, Spokane Valley
Lead Sponsor
Gradalis, Inc.
INDUSTRY